Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc.

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic diseases, particularly fatty liver diseases such as nonalcoholic steatohepatitis (NASH).

Sagimet Biosciences

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors. For more information, please visit www.sagimet.com.

New Enterprise Associates

Qianhai Ark

PFM Health Sciences

Altium Capital

Ascletis

HM Capital

Huimei Capital

Invus

Kleiner Perkins

Rock Springs Capital

Sagimet Biosciences’ fourth quarter and full year 2023 financial results and corporate updates are now available: https://lnkd.in/gUeJm35v

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors. Learn more here: https://lnkd.in/gFavsWPF

Join Sagimet Biosciences (#SGMT) for a conference call and webcast on Thurs. June 13 at 12:30pm ET featuring Rohit Loomba, M.D., M.H.Sc., (MASLD Research Center, University of California San Diego), to discuss positive data from the FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

Attend: https://lnkd.in/g6v4DdAb

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
 
Press Release: https://lnkd.in/gWFhiskW
Presentation: https://lnkd.in/gZDt4Csw

Sagimet looks forward to presenting multiple posters at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting and engaging with the #NASH community

View full data release here: https://lnkd.in/gXN9ZHS3 

 #biotech #NASH #denifanstat #FASN #AASLD #TLM23

Join Sagimet Biosciences (#SGMT) for a virtual investor and analyst day on Thurs. May 23 at 1:00pm ET featuring Scott L. Friedman, MD (Icahn School of Medicine at Mount Sinai), who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis #MASH.

Register here: https://lnkd.in/g46Pa7Jy

COM:SAGIMET

Sagimet Biosciences

Last Close

4.50

22/11 21:00

Market Cap

101.81M

Beta: -

Volume Today

404.41K

Avg: -

People Not Available